Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05348993 · ClinicalTrials.gov registry record · Phase 2
Single or Repeat Dose of G03-52-01 in Adult Subjects
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 622
- Enrollment target
NCT05348993: Completed Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
NCT05348993 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 622 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (368% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05348993, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 622 participants
- Enrollment target
Study Summary
A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial
Primary Outcome
An AE was any unfavourable and unintended sign, symptom, or disease temporarily associated with the use of investigational product (IP), whether or not related to the IP. A SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a congenital abnormality/birth defect, or caused any persistent or significant incapacity or substantial disruption of the ability to c
Interventions
- DRUG Placebo
- DRUG G03-52-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 2 |
What the finished NCT05348993 record still lists
NCT05348993 is an interventional study that assigns participants to a tested intervention. The registered 622 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (368% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05348993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05348993 about?
NCT05348993 is a clinical study titled "Single or Repeat Dose of G03-52-01 in Adult Subjects". A Phase 2, randomized, double-blind, placebo-controlled single or repeat dose trial
What is the current status of trial NCT05348993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 622 participants. The study started on 2022-06-15. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT05348993?
The interventions under investigation include: Placebo (DRUG), G03-52-01 (DRUG).
Who is sponsoring clinical trial NCT05348993?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05348993's enrollment target sits among peer trials
622 52nd of 2000 higher than 1,949 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712355 · 621 participants · Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI